IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

Autor: Kristian Reich, Kilian Eyerich, Knut Schäkel, Peter Weisenseel, Andreas Pinter, Khusru Asadullah, Sven Wegner, Ernesto J Muñoz-Elias, Holger Bartz, Friedmann J H Taut

Publikováno v: BMJ Open, Vol 11, Iss 9 (2021)

Background Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may result in changes to the clinical disease course versus later interventi

Externí odkaz: https://doaj.org/article/673be33cf2a54e4aba93d38bcb985891

[Immune-mediated inflammatory diseases in Germany : A cross-sectional analysis of comorbidities and pharmacotherapy]

Autor: Jan, Leipe, Renate, Schmelz, Gabriela, Riemekasten, Diamant, Thaçi, Jörg, Henes, Knut, Schäkel, Andreas, Pinter, Michael, Sticherling, Joanna, Wegner, Stefano, Fusco, Miriam, Linke, Valeria, Weber, Karina C, Manz, Holger, Bartz, Marit, Roecken, Sandra, Schmidt, Bimba F, Hoyer

Publikováno v: Zeitschrift fur RheumatologieLiteratur.

Immune-mediated inflammatory diseases (IMID) can lead to a substantial disease burden for those affected, in particular by the concomitant occurrence of other IMIDs or in the presence of comorbidities. The care of patients with IMIDs is complex and i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::762a22344daf29b231bff5d2921513bc
https://pubmed.ncbi.nlm.nih.gov/36600054

Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients with Associated Sjögren's Syndrome: Post-hoc Analyses from the EMBODY Trials

Autor: S. Bongardt, Guy Meno-Tetang, William A. Wegener, W. Koetse, Anthony Shock, Marga Oortgiesen, David M. Goldenberg, Xavier Mariette, Jacques-Eric Gottenberg, Gordana Kosutic, Valérie Devauchelle-Pensec, C. Galateanu, Simon J. Bowman, Hendrika Bootsma, Thomas Dörner, Caroline Gordon, Holger Bartz

Publikováno v: Arthritis & rheumatology
Arthritis & rheumatology, Wiley, 2018, ⟨10.1002/art.40425⟩
Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis & Rheumatology, 70(5), 763-773. Wiley

Objective. EMBODY 1 (ClinicalTrials.gov identifier: NCT01262365) and EMBODY 2 (ClinicalTrials.gov identifier: NCT01261793) investigated the efficacy and safety of epratuzumab, a CD22-targeted humanized monoclonal IgG antibody, in patients with system

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::254e87d0618ca01c7ec9833dee2f7d4a
https://hal.archives-ouvertes.fr/hal-01706654

Airway epithelial cells modify immune responses by inducing an anti-inflammatory microenvironment

Autor: Holger Bartz, Alexander H. Dalpke, Anja K. Mayer, Lotte M. Schmidt, Fabian Fey

Publikováno v: European Journal of Immunology. 38:1689-1699

The upper airways are prone to contact with pathogenic as well as non-pathogenic microbes, therefore immune recognition principles have to be tightly controlled. Here we show that human BEAS-2B bronchial epithelial cells inhibited secretion of the pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b808086950dad07fd018407f64560f93
https://doi.org/10.1002/eji.200737936

Poly-guanosine strings improve cellular uptake and stimulatory activity of phosphodiester CpG oligonucleotides in human leukocytes

Autor: Klaus Heeg, Yuri Mendoza, Holger Bartz, Alexander H. Dalpke, Miriam Gebker, Till Fischborn

Publikováno v: Vaccine. 23:148-155

CpG-oligonucleotides (CpG-ODN) have been shown to exert strong immuno-stimulatory effects through activation of Toll-like receptor 9 (TLR-9). However, TLR-9 triggering takes place in endosomal compartments and thus CpG-ODN have to be taken up prior t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8309a14866f9c4bc58b13eeb68c7c169
https://doi.org/10.1016/j.vaccine.2004.05.020